Genomic differences between O6-methylguanine-DNA methyltransferase proficient (Mex+) and deficient (Mex-) cell lines: possible role of genetic and epigenetic changes in conversion of Mex+ into Mex-.

Biochem Biophys Res Commun

Kernforschungszentrum Karlsruhe, Institut für Genetik und Toxikologie, Karlsruhe, Germany.

Published: March 1992

Cell lines that possess O6-methylguanine-DNA methyltransferase (MGMT) repair activity (Mex+ phenotype) or are deficient for MGMT (Mex-) are compared at genomic level. It is shown that 1) 208F rat cells do not contain the MGMT gene, as detected by Southern blot hybridization. 2) Mex- HeLa MR and CHO-9 cells express very low amounts of MGMT mRNA, as detected by PCR. The size of the MGMT specific PCR product was slightly smaller than that generated from Mex+ HeLa S3 cells. 3) HeLa MR, compared to various human Mex+ cell lines, shows a restriction fragment length polymorphism indicating mutational alteration of MGMT gene sequences. 4) Mex- cells (HeLa MR) and cells that express very low MGMT activity (GM637) exhibit hypomethylation of the MGMT gene as revealed by MspI/HpaII restriction digests. 5) Exposure of Mex- cells to 5-azacytidine and selection with N-hydroxyethyl-N-chloroethylnitrosourea (HeCNU) did not yield Mex+ revertants. With V79 cells treated with 5-azacytidine clones resistant to HeCNU were isolated. These cells were MGMT deficient and not cross-resistant to N-methyl-N'-nitro-N-nitrosoguanidine indicating the existance of a defence mechanism other than MGMT against chloroethylating agents. The data suggest down-regulation of MGMT transcription accompanied by decreasing CpG methylation, but in some cell lines also mutational alterations to be involved in extinction of the Mex+ phenotype.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(05)80315-8DOI Listing

Publication Analysis

Top Keywords

cell lines
16
mgmt gene
12
mgmt
11
o6-methylguanine-dna methyltransferase
8
mex- cell
8
mex+ phenotype
8
cells
8
cells mgmt
8
cells express
8
express low
8

Similar Publications

Advancing cancer therapy with custom-built alternating electric field devices.

Bioelectron Med

January 2025

School of Pharmacy, Biodiscovery Institute & Boots Science Building, University of Nottingham, Nottingham, NG7 2RD, UK.

Background: In glioblastoma (GBM) therapy research, tumour treating fields by the company Novocure™, have shown promise for increasing patient overall survival. When used with the chemotherapeutic agent temozolomide, they extend median survival by five months. However, there is a space to design alternative systems that will be amenable for wider use in current research.

View Article and Find Full Text PDF

Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology.

Radiat Oncol

January 2025

Department of Radiotherapy and Radiooncology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany.

Background: Medulloblastoma is the most common malignant pediatric brain tumor, typically treated with normofractionated craniospinal irradiation (CSI) with an additional boost over about 6 weeks in children older than 3 years. This study investigates the sensitivity of pediatric medulloblastoma cell lines to different radiation fractionation schedules. While extensively studied in adult tumors, these ratios remain unknown in pediatric cases due to the rarity of the disease.

View Article and Find Full Text PDF

The generation of retinal models from human induced pluripotent stem cells holds significant potential for advancing our understanding of retinal development, neurodegeneration, and the in vitro modeling of neurodegenerative disorders. The retina, as an accessible part of the central nervous system, offers a unique window into these processes, making it invaluable for both study and early diagnosis. This study investigates the impact of the Frontotemporal Dementia-linked IVS 10 + 16 MAPT mutation on retinal development and function using 2D and 3D retinal models derived from human induced pluripotent stem cells.

View Article and Find Full Text PDF

Extracellular matrix stiffness regulates colorectal cancer progression via HSF4.

J Exp Clin Cancer Res

January 2025

Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.

Background: Colorectal cancer (CRC) has high incidence and mortality rates, with severe prognoses during invasion and metastasis stages. Despite advancements in diagnostic and therapeutic technologies, the impact of the tumour microenvironment, particularly extracellular matrix (ECM) stiffness, on CRC progression and metastasis is not fully understood.

Methods: This study included 107 CRC patients.

View Article and Find Full Text PDF

The histone demethylase KDM5C enhances the sensitivity of acute myeloid leukemia cells to lenalidomide by stabilizing cereblon.

Cell Mol Biol Lett

January 2025

Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Key Laboratory of Drug Research for Prevention and Treatment of Hyperlipidemic Diseases, Soochow University, 199 Ren'ai Road, Suzhou, 215123, Jiangsu, China.

Background: The protein cereblon (CRBN) mediates the antileukemia effect of lenalidomide (Len). Len binds to CRBN, recruits IKZF1/IKZF3, and promotes their ubiquitination and degradation, through which Len exhibits its antileukemia and antimyeloma activity. Therefore, the protein level of CRBN might affect the antiproliferative effect of Len.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!